Aflibercept Biosimilar (Clover Biopharmaceuticals)

阿柏西普生物类似药（三叶草）

Report date: 2022/04/21 20:00:47

Base Information

Drug NameAflibercept Biosimilar (Clover Biopharmaceuticals)
Drug Alias NameSCB-420
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein > Fc fusion proteinBiologics > Biosimilar
Mechanisms of ActionPlacental Growth Factor inhibitorsVascular endothelial growth factor A inhibitors
TargetsPlacental Growth FactorVascular endothelial growth factor A
Therapy Area/IndicationsDiabetic macular oedemaWet age-related macular degenerationMacular Degeneration
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesClover Biopharmaceuticals Ltd
China Registration ClassN/A

Develop Information

Active CompaniesClover Biopharmaceuticals Ltd
Inactive CompaniesClover Biopharmaceuticals Aus Pty Ltd
Active IndicationsDiabetic macular oedemaMacular Degeneration
Inactive IndicationsWet age-related macular degeneration

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG